Cancer Patient Guide

Brain Cancer & GBM: Expert Insights for Treatment Decisions

Curated from expert webinars (part of 150+ across all cancer types) hosted by Cancer Patient Lab, a 501(c)(3) nonprofit, featuring insights from Dr. Wayne Carter, Al Musella, and Dr. Saskia Biskup. Covers temozolomide, Optune, IDH and MGMT molecular markers, clinical trials, and emerging immunotherapy approaches.

Expert Panel

Oncologists and researchers who contributed insights through Cancer Patient Lab webinars

Wayne Carter, DVM, PhD

Brain cancer research and novel treatment approaches

Al Musella

Brain tumor patient advocacy and clinical trial navigation

Saskia Biskup, MD, PhD

Genomic profiling and precision medicine for brain tumors

Tony Letai, MD, PhD

Functional precision medicine — testing drugs on cancer cells

Lisa Butterfield

Cancer vaccines and immunotherapy

Selin Kurnaz

Finding the right cancer clinical trial

Massive Bio

Treatment Topics

Key treatment areas covered across our brain cancer webinar series

Standard of Care: Surgery, Radiation & Temozolomide

The Stupp protocol — maximal safe resection followed by concurrent radiation and temozolomide, then adjuvant temozolomide — remains the standard of care for newly diagnosed glioblastoma. MGMT promoter methylation status is the strongest predictor of temozolomide benefit. Extent of surgical resection significantly impacts outcomes, making an experienced neurosurgical center critical.

Optune: Tumor Treating Fields (TTFields)

Optune delivers low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. Added to maintenance temozolomide, it improved median survival by ~5 months in the EF-14 trial. The device requires wearing arrays on the shaved scalp for at least 18 hours daily. Compliance correlates with benefit. Newer generation devices and combinations with other treatments are being studied.

Clinical Trials & Emerging Therapies

Brain cancer — particularly GBM — has seen limited drug approvals, making clinical trials especially important. Emerging approaches include cancer vaccines (personalized neoantigen vaccines, dendritic cell vaccines), checkpoint inhibitors (especially for hypermutated tumors), oncolytic viruses, convection-enhanced delivery, and novel targeted therapies. Al Musella maintains one of the most comprehensive brain tumor clinical trial databases.

Molecular Markers: IDH, MGMT & Beyond

The 2021 WHO classification of brain tumors now requires molecular markers alongside histology. IDH mutations define a biologically distinct (and better-prognosis) subset of gliomas, with vorasidenib recently approved for IDH-mutant low-grade gliomas. MGMT methylation predicts temozolomide response. 1p/19q codeletion identifies oligodendrogliomas. Dr. Saskia Biskup discusses comprehensive genomic profiling for brain tumors.

Supportive Care & Quality of Life

Brain cancer treatment often involves managing seizures, cerebral edema (with dexamethasone), cognitive changes, and fatigue. Anti-seizure medications, physical and occupational therapy, and neuropsychological support are integral parts of care. Early palliative care consultation improves quality of life. Self-care strategies and caregiver support are especially important given the cognitive effects of brain tumors.

Common Questions from Brain Cancer Patients

Answered by Navis AI, informed by expert webinars and medical guidelines

Testing Services for Brain Cancer

Genomic testing, liquid biopsy, and molecular profiling services relevant to brain cancer

Browse all 369 services →

Brain Cancer Webinars

From Cancer Patient Lab — a 501(c)(3) nonprofit

Get Personalized Brain Cancer Insights

Upload your pathology report, genomic test, or lab results. Our AI translates them into plain English and matches you to relevant services and clinical trials.

This page is for informational purposes only and does not constitute medical advice. Content is curated from expert webinars hosted by Cancer Patient Lab, a 501(c)(3) nonprofit. Always consult your oncologist for treatment decisions. Meet our team →